Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study

Jong-Hyun Jeong,1 Won-Myong Bahk,1 Young Sup Woo,1 Ho-Jun Seo,1 Seung-Chul Hong,1 Duk-In Jon,2 Kyung Joon Min,3 Bo-Hyun Yoon41Department of Psychiatry, College of Medicine, The Catholic of University of Korea, Seoul, 2Department of Psychiatry, College of Medicine, Hallym University, Anyang, 3Departm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeong JH, Bahk WM, Woo YS, Seo HJ, Hong SC, Jon DI, Min KJ, Yoon BH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/992e73b6a7004a43ab3b1bc882a883e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:992e73b6a7004a43ab3b1bc882a883e5
record_format	dspace
spelling	oai:doaj.org-article:992e73b6a7004a43ab3b1bc882a883e52021-12-02T00:29:03ZEfficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study1176-63281178-2021https://doaj.org/article/992e73b6a7004a43ab3b1bc882a883e52013-02-01T00:00:00Zhttp://www.dovepress.com/efficacy-of-quetiapine-in-patients-with-bipolar-i-and-ii-depression-a--a12164https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Jong-Hyun Jeong,1 Won-Myong Bahk,1 Young Sup Woo,1 Ho-Jun Seo,1 Seung-Chul Hong,1 Duk-In Jon,2 Kyung Joon Min,3 Bo-Hyun Yoon41Department of Psychiatry, College of Medicine, The Catholic of University of Korea, Seoul, 2Department of Psychiatry, College of Medicine, Hallym University, Anyang, 3Department of Neuropsychiatry, College of Medicine, Chung-Ang University, Seoul, 4Naju National Hospital, Naju, KoreaPurpose: To evaluate and compare the therapeutic efficacy of quetiapine in bipolar I and II depression patients in the clinical setting.Patients and methods: This was an 8-week, multicenter, open-label, observational study for bipolar depression. The dosage of quetiapine was flexible, and concomitant medications were permitted on clinician&#39;s judgments. A total of 1097 patients were enrolled, and 764 bipolar depression patients who exhibited good therapeutic compliance (&gt;75% compliance rate) were analyzed.Results: Clinical Global Impression &ndash; Bipolar scale and Montgomery&ndash;Asberg Depression Rating Scale scores were significantly improved at weeks four and eight compared with the baseline scores. At the end of the 8-week study, the response rate was 58.9%, and the remission rate was 42.1%. However, there were no significant differences in the response and remission rates between bipolar I and II disorder (BD-I and BD-II) patients (response rate 60.1% versus 56.3%; remission rate 44.5% versus 37.0%). Montgomery&ndash;Asberg Depression Rating Scale score at baseline (&beta; = 0.612, P &lt; 0.001), duration of current episode (&beta; = &minus;0.152, P = 0.001), and presence of remission on previous episode (&beta; = 0.111, P = 0.012) were significantly associated with improvements in depressive symptoms. Fatigue (16.0%), somnolence (14.9%), and manic/hypomanic switching (0.6% at week four, 0.3% at week eight) were observed throughout the study period.Conclusion: The results of this study suggest that quetiapine improves depressive symptoms in BD-I and BD-II patients with a minimal incidence of manic switching. The therapeutic efficacy of quetiapine increased with time. Quetiapine could be an effective and safe modality for the treatment of BD-I and BD-II.Keywords: bipolar depression, quetiapine, therapeutic efficacy, observational studyJeong JHBahk WMWoo YSSeo HJHong SCJon DIMin KJYoon BHDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 197-204 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Jeong JH Bahk WM Woo YS Seo HJ Hong SC Jon DI Min KJ Yoon BH Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
description	Jong-Hyun Jeong,1 Won-Myong Bahk,1 Young Sup Woo,1 Ho-Jun Seo,1 Seung-Chul Hong,1 Duk-In Jon,2 Kyung Joon Min,3 Bo-Hyun Yoon41Department of Psychiatry, College of Medicine, The Catholic of University of Korea, Seoul, 2Department of Psychiatry, College of Medicine, Hallym University, Anyang, 3Department of Neuropsychiatry, College of Medicine, Chung-Ang University, Seoul, 4Naju National Hospital, Naju, KoreaPurpose: To evaluate and compare the therapeutic efficacy of quetiapine in bipolar I and II depression patients in the clinical setting.Patients and methods: This was an 8-week, multicenter, open-label, observational study for bipolar depression. The dosage of quetiapine was flexible, and concomitant medications were permitted on clinician&#39;s judgments. A total of 1097 patients were enrolled, and 764 bipolar depression patients who exhibited good therapeutic compliance (&gt;75% compliance rate) were analyzed.Results: Clinical Global Impression &ndash; Bipolar scale and Montgomery&ndash;Asberg Depression Rating Scale scores were significantly improved at weeks four and eight compared with the baseline scores. At the end of the 8-week study, the response rate was 58.9%, and the remission rate was 42.1%. However, there were no significant differences in the response and remission rates between bipolar I and II disorder (BD-I and BD-II) patients (response rate 60.1% versus 56.3%; remission rate 44.5% versus 37.0%). Montgomery&ndash;Asberg Depression Rating Scale score at baseline (&beta; = 0.612, P &lt; 0.001), duration of current episode (&beta; = &minus;0.152, P = 0.001), and presence of remission on previous episode (&beta; = 0.111, P = 0.012) were significantly associated with improvements in depressive symptoms. Fatigue (16.0%), somnolence (14.9%), and manic/hypomanic switching (0.6% at week four, 0.3% at week eight) were observed throughout the study period.Conclusion: The results of this study suggest that quetiapine improves depressive symptoms in BD-I and BD-II patients with a minimal incidence of manic switching. The therapeutic efficacy of quetiapine increased with time. Quetiapine could be an effective and safe modality for the treatment of BD-I and BD-II.Keywords: bipolar depression, quetiapine, therapeutic efficacy, observational study
format	article
author	Jeong JH Bahk WM Woo YS Seo HJ Hong SC Jon DI Min KJ Yoon BH
author_facet	Jeong JH Bahk WM Woo YS Seo HJ Hong SC Jon DI Min KJ Yoon BH
author_sort	Jeong JH
title	Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
title_short	Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
title_full	Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
title_fullStr	Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
title_full_unstemmed	Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
title_sort	efficacy of quetiapine in patients with bipolar i and ii depression: a multicenter, prospective, open-label, observational study
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/992e73b6a7004a43ab3b1bc882a883e5
work_keys_str_mv	AT jeongjh efficacyofquetiapineinpatientswithbipolariandiidepressionamulticenterprospectiveopenlabelobservationalstudy AT bahkwm efficacyofquetiapineinpatientswithbipolariandiidepressionamulticenterprospectiveopenlabelobservationalstudy AT wooys efficacyofquetiapineinpatientswithbipolariandiidepressionamulticenterprospectiveopenlabelobservationalstudy AT seohj efficacyofquetiapineinpatientswithbipolariandiidepressionamulticenterprospectiveopenlabelobservationalstudy AT hongsc efficacyofquetiapineinpatientswithbipolariandiidepressionamulticenterprospectiveopenlabelobservationalstudy AT jondi efficacyofquetiapineinpatientswithbipolariandiidepressionamulticenterprospectiveopenlabelobservationalstudy AT minkj efficacyofquetiapineinpatientswithbipolariandiidepressionamulticenterprospectiveopenlabelobservationalstudy AT yoonbh efficacyofquetiapineinpatientswithbipolariandiidepressionamulticenterprospectiveopenlabelobservationalstudy
_version_	1718403692749651968

Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study

Ejemplares similares